

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**EXPECTED INCREASE IN PROFIT FOR  
SHANGHAI MICROPORT ENDOVASCULAR MEDTECH (GROUP) CO., LTD.  
FOR THE SIX MONTHS ENDED 30 JUNE 2023**

The board of directors (the “**Board**”) of MicroPort Scientific Corporation (the “**Company**”, together with its subsidiaries (the “**Group**”)) wishes to inform shareholders of the Company and potential investors that, based on the information currently available to the management, Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (“**EV MedTech**”) is expected to record an increase in its profit for the six months ended 30 June 2023.

EV MedTech is owned as to 46.34% by the Group and its results are consolidated with the financial statements of the Company. The shares of EV MedTech are listed on the science and technology innovation board of the Shanghai Stock Exchange.

For the six months ended 30 June 2023, the revenue of EV MedTech is expected to be between RMB596.44 million and RMB633.144 million, representing an increase of between approximately 30% and 38% as compared with the same period last year. The net profit attributable to the equity owners of EV MedTech is expected to be between RMB268.7956 million and RMB279.5474 million, representing an increase of between approximately 25% and 30% as compared with the same period last year.

The increases in revenue and profit were mainly attributable to greater demand for various major products of EV MedTech as a result of the rapid recovery of the number of surgeries in hospitals across the country with the restoration of medical order after the Spring Festival. Meanwhile, EV MedTech firmly implements its market penetration strategy in low-tier regions, increases its market promotion and continues to push forward the hospital admission, promotion, and sales of its products in different regions, bringing a rapid growth in its overall sales and net profit in first half compared with the same period last year. Besides, the numbers of hospitals entered and terminal implants for the newly launched products of EV MedTech, such as the Fontus<sup>®</sup> Branched Surgical Stent Graft System and Talos<sup>®</sup> Thoracic Stent Graft System, have both achieved a rapid growth.

Shareholders and investors are reminded that the financial information of EV MedTech above was prepared in accordance with PRC accounting standards, and is limited solely to the operation of EV MedTech and unrelated to the other subsidiaries of the Group. Such information is unaudited and has not been reviewed by the auditors or the audit committee of the Company, and does not (a) exclude intra-group transactions, (b) include all the business of the Group, or (c) represent or provide a full picture of the operation or status of the Group. **Shareholders and potential investors of the Company are reminded to exercise caution when dealing in the securities of the Company.**

By order of the Board  
**MicroPort Scientific Corporation**  
**Dr. Zhaohua Chang**  
*Chairman*

Shanghai, the PRC, 11 July 2023

*As at the date of this announcement, the executive Director is Dr. Zhaohua Chang; the non-executive Directors are Mr. Hiroshi Shirafuji, Mr. Norihiro Ashida and Mr. Hongliang Yu; and the independent non-executive Directors are Mr. Jonathan H. Chou, Dr. Guoen Liu and Mr. Chunyang Shao.*

*\* For identification purpose only*